Surgical Site Infections Market

Market Overview:

The surgical site infections market reached a value of USD 700.2 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 1,238.5 Million by 2035, exhibiting a growth rate (CAGR) of 5.32% during 2025-2035.

The surgical site infections market has been comprehensively analyzed in IMARC's new report titled "Surgical Site Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Surgical site infections (SSI) refer to a medical condition that arises after surgery in the area of the body where the procedure was conducted. It mainly occurs due to the colonization of a surgical incision by infectious agents, such as bacteria or fungi. SSI can either be superficial, simply affecting the skin, or more serious, affecting organs, implanted materials, or tissues beneath the skin. The disease symptoms usually manifest within thirty days of a surgical operation. Some of the common indications associated with this illness include redness, pain, fever, delayed healing, tenderness, swelling, etc. Individuals suffering from the condition may also experience drainage of cloudy fluid or pus from the wound site. The diagnosis of surgical site infections typically requires a combination of the patient’s medical history, clinical features, and laboratory studies. The healthcare provider may also collect a wound swab to determine the presence of disease-causing microorganisms. Additionally, ultrasonography, which can detect abscesses within a surgical site and regulate their drainage, is utilized to confirm a diagnosis among patients.

The increasing cases of endogenous and exogenous infections caused by contamination of the operative site by microorganisms during the procedure are primarily driving the surgical site infections market. In addition to this, the rising incidence of various risk factors, including increased length of surgical duration, a weakened immune system, certain co-morbidities like diabetes and cancer, etc., is also bolstering the market growth. Furthermore, the widespread adoption of antibiotic drugs, such as cefazolin, metronidazole, vancomycin, clindamycin, etc., for treating the ailment is acting as another significant growth-inducing factor. These medications prevent disease progression by destroying or slowing the proliferation of microorganisms causing the infection, thereby helping to promote wound healing. Additionally, several government bodies and non-governmental organizations are supporting numerous health education campaigns to create general awareness about preventive measures, the benefits of early diagnosis, and treatment alternatives for SSI. This, in turn, is further creating a positive outlook for the market. Moreover, the emerging popularity of combination therapy involving nasal mupirocin and a chlorhexidine body wash, since they can optimally decolonize patients with bacterial growth and reduce the risk of microbial contamination, is expected to drive the surgical site infections market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the surgical site infections market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for surgical site infections and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the surgical site infections market in any manner.

Recent Developments:

• In December 2024, PolyPid announced that the independent Data Safety Monitoring Board (DSMB) had reviewed unblinded efficacy data from the first 430 patients enrolled in the SHIELD II Phase 3 trial evaluating D-PLEX100 for the prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
• In June 2024, Destiny Pharma announced that the UK Medicines and Healthcare Regulatory Agency (MHRA) granted an innovation passport to XF-73 nasal under the innovative licensing and access pathway (ILAP) for the prevention of post-surgical site infections.

Key Highlights:

• SSIs occur in 2–4% of all patients receiving inpatient surgical operations.
• According to the subgroup analysis by WHO area and survey period, the incidence of SSI was 2.7% and 2.5%, respectively.
• Surgical site infections are responsible for 20% of all healthcare-associated infections and are linked to a 2-to 11-fold increased risk of mortality, with 75% of SSI-related deaths directly attributed to the infection.
• The African area has the highest prevalence (2.7%).
• In research done by the National Healthcare Safety Network (NHSN) after collecting information from 850,000 general surgeries conducted in the United States, it was discovered that the overall incidence of SSI was equivalent to 1.9%.

Drugs:

D-PLEX100 is intended to deliver localized, sustained, and regulated anti-bacterial activity directly at the surgical site to prevent surgical site infections. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology combines with Active Pharmaceutical Ingredients, allowing for the prolonged and continuous dissolution of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with the potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site.

Exeporfinium Chloride (XF-73) is an innovative therapeutic agent for Phase 2 trials, targeting surgical site and staphylococcal infections. The substance alters bacterial cell membrane permeability, thus better absorbing antimicrobial agents. Disruption of bacterial membranes by XF-73 increased bacteria susceptibility to antibiotics, thus fighting antibiotic resistance and decreasing the post-surgical infection rates.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the surgical site infections market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the surgical site infections market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current surgical site infections marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the surgical site infections market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the surgical site infections market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the surgical site infections market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of incident cases (2019-2035) of surgical site infections across the seven major markets?
• What is the number of incident cases (2019-2035) of surgical site infections by age across the seven major markets?
• What is the number of incident cases (2019-2035) of surgical site infections by gender across the seven major markets?
• What is the number of incident cases (2019-2035) of surgical site infections by type across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with surgical site infections across the seven major markets?
• What is the size of the surgical site infections patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of surgical site infections?
• What will be the growth rate of patients across the seven major markets?
   

Surgical Site Infections: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for surgical site infections drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the surgical site infections market?
• What are the key regulatory events related to the surgical site infections market?
• What is the structure of clinical trial landscape by status related to the surgical site infections market?
• What is the structure of clinical trial landscape by phase related to the surgical site infections market?
• What is the structure of clinical trial landscape by route of administration related to the surgical site infections market?